Gleevec Extends Post-Surgery GIST Survival Significantly; Wins Full Adjuvant Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients who took Novartis’ Gleevec for three years after surgery to remove gastrointestinal stromal tumors had a 54% reduction in risk of recurrence and a 55% reduction in risk of death compared to patients who took it for only one year.